HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors.

AuthorsA Chuansumrit, N Sirachainan, M Panuwannakorn, P Wongwerawattanakoon, P Kadegasem, W Choeyprasert, W Sasanakul
JournalHaemophilia : the official journal of the World Federation of Hemophilia (Haemophilia) Vol. 19 Issue 3 Pg. e182-3 (May 2013) ISSN: 1365-2516 [Electronic] England
PMID23600908 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Coagulation Factor Inhibitors
  • Factor VIII
  • Factor VIIa
Topics
  • Adolescent
  • Blood Coagulation Factor Inhibitors (blood)
  • Exons
  • Factor VIII (antagonists & inhibitors, genetics, immunology)
  • Factor VIIa (therapeutic use)
  • Gene Deletion
  • Hemophilia A (drug therapy)
  • Humans
  • Immune Tolerance
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: